Bio­Marin ‘turn­ing the cor­ner’ on prof­its with op­ti­mism on Vox­zo­go, Roc­ta­vian — but ques­tions re­main

Bio­Marin fi­nal­ly is ‘turn­ing the cor­ner’ on prof­itabil­i­ty in 2022, CEO Jean-Jacques Bi­en­aimé said in its earn­ings call yes­ter­day. And while in­vestors gen­er­al­ly agreed with that, they al­so have a lot of spe­cif­ic prod­uct ques­tions that Bio­Marin isn’t able to ful­ly an­swer just yet.

For in­stance, on its achon­dropla­sia drug Vox­zo­go spe­cif­ic to chil­dren in its youngest age co­hort ages 0-5, Bio­Marin de­tailed new top-line Phase II da­ta and a miss, with no sta­tis­ti­cal sig­nif­i­cance found among the young pa­tients. How­ev­er ex­ec­u­tives cau­tioned the da­ta is new, re­ceived “on­ly 24 hours ago,” and “a lit­tle com­pli­cat­ed in sig­nal and noise” dur­ing its earn­ings call Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER